Article
Activating mutations in ALK provide a therapeutic target in neuroblastoma.
Nature - 16 Oct 2008
George Rani E, Sanda Takaomi, Hanna Megan, Fröhling Stefan, Luther William, Zhang Jianming, Ahn Yebin, Zhou Wenjun, London Wendy B, McGrady Patrick, Xue Liquan, Zozulya Sergey, Gregor Vlad E, Webb Thomas R, Gray Nathanael S, Gilliland D Gary, Diller Lisa, Greulich Heidi, Morris Stephan W, Meyerson Matthew, Look A Thomas
Abstract excerpt
Neuroblastoma, an embryonal tumour of the peripheral sympathetic nervous system, accounts for approximately 15% of all deaths due to childhood cancer. High-risk neuroblastomas are rapidly progressive; even with intensive myeloablative chemotherapy, relapse is common and almost uniformly fatal. Here we report the detection of previously unknown mutations in the ALK gene, which encodes a receptor tyrosine kinase,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.